Clinical and Translational Research Services Shared Resource

临床和转化性研究服务(CTRS)的主要目的是促进、支持和确保以尽可能高效和安全的方式产生和进行高影响的患者研究，以大幅减轻夏威夷和其他地区人民的癌症负担。减少某些少数民族和弱势群体所经历的不同的癌症负担是一个主要目标。在没有大学医院的情况下，CTRS提供了基础设施，使夏威夷的社区提供者和他们所服务的患者能够获得NCI/NIH赞助的少数族裔临床肿瘤学计划(MB-CCOP)、国家外科辅助乳肠计划(NSABP)和研究项目赠款的临床试验。这些试验为夏威夷患者提供了最有希望的研究机会，并将夏威夷独特的多种族人口贡献给大型多中心临床试验。此外，该系统通过参与该系统的研究和相关的继续教育活动，使癌症护理提供者保持在最先进的科学护理的前沿。这确保了在大多数情况下，患者不必离开岛屿就可以获得最好的医疗服务，并减少了患者在接受癌症治疗时因旅行超过2500英里而产生额外费用或与家人和社会支持系统分离的机会。CTRS支持临床和转化性研究的社区访问和传播水平，这在其他NCI指定的癌症中心很少看到。在没有大学医疗中心的情况下，所有临床调查都是通过社区提供者进行的。这提供了无与伦比的机会，加快了从长凳到床边再到社区应用的发现进程。随着今年夏威夷癌症联盟(HCC)的成立，夏威夷大学癌症中心(UHCC)将开发一项由研究人员发起的充满活力的临床和转化研究活动。CTRS将支持这些方案的开发和实施，作为第一优先事项，以迅速将UCC研究计划的发现转化为基于社区的临床应用。CTRS的很大一部分致力于促进未得到充分服务的少数群体参与临床试验。我们在这方面取得了实质性进展。通常每年有200多名新受试者参加所有阶段的癌症临床试验，夏威夷少数民族的比例代表。夏威夷原住民和其他太平洋岛民约占所有癌症患者的12%，他们经历了最糟糕的癌症结果，占入选患者的25%。

The primary purpose of Clinical and Translational Research Services (CTRS) is to facilitate, support, and assure the generation and conduct of high impact patient research in the most efficient and safe way possible to substantially reduce the burden of cancer for the people of Hawai'i and elsewhere. Reducing the disparate burden of cancer experienced by certain minorities and vulnerable populations is a primary goal. In the absence of a university hospital, CTRS has provided the infrastructure to give Hawai'i's community-based providers and the patients they serve access to NCI/NIH-sponsored clinical trials from Minority-based Clinical Oncology Program (MB-CCOP), National Surgical Adjuvant Breast and Bowel Project (NSABP) and research project grants. These trials have provided Hawai'i patients with access to the most promising research opportunities and contribute Hawai'i's unique multi-ethnic population to large multicenter clinical trials. Furthermore, the system maintains cancer care providers at the cutting edge of state-of-the-science care through their participation in the research and the associated continuing education activities of the system. This assures that in most cases patients can access the best care without having to leave the islands and reduces the chance of patients incurring additional costs to travel more than 2500 miles for care, or be separated from their families and social support systems while receiving cancer care. CTRS supports a level of community access and dissemination for clinical and translational research that is seldom seen at other NCI-designated cancer centers. In the absence of a university medical center, all clinical investigation is conducted through community-based providers. This gives unparalleled opportunity to accelerate the progression of discoveries from bench to bedside to community application. With the formation of the Hawai'i Cancer Consortium (HCC) this year, the University of Hawai'i Cancer Center (UHCC) will develop a vibrant clinical and translational research activity of investigator-initiated protocols. CTRS will support the development and conduct of these protocols as a first priority to rapidly translate discoveries of the UHCC's research programs into community-based clinical applications. A large component of CTRS is committed to facilitating the participation of underserved minorities in clinical trials. We have made substantial progress in this respect. Usually more than 200 new subjects each year are enrolled on cancer clinical trials of all phases, with proportional representation of Hawai'i's ethnic minorities. Native Hawaiians and other Pacific Islanders, who represent about 12% of all cancer patients and experience the worst cancer outcome, constitute 25% of patients enrolled.